美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM)

0.0058

0.0000

成交量：- -

成交額：- -

市值：5.73萬

市盈率：0.02

高：0.0058

開：0.0058

低：0.0058

收：0.0058

52周最高：0.0058

52周最低：0.0058

股本：987.80萬

流通股本：- -

量比：4.57

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.3636

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM)

交易所：

NYSE

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.calidibio.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Calidi Biotherapeutics, Inc.成立時是特拉華州的一家臨床階段免疫腫瘤公司，該公司是一家臨床階段的免疫腫瘤學公司，正在開發基於同種異體干細胞的專有平台，以增強和遞送溶瘤病毒以及可能的分子給癌症患者。該公司目前正在開發兩個基於干細胞的專有平台和一個包膜牛痘病毒平台，旨在保護溶瘤病毒，無論是天然的還是工程的，不被患者的免疫防禦所中和，從而允許腫瘤細胞受到更大的感染，並導致溶瘤病毒的抗腫瘤活性比傳統的“裸”溶瘤病毒療法有潛在的改善。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CLDI.WS/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLDI.WS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI.WS\",,,,,undefined,":{"symbol":"CLDI.WS","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM)","latestPrice":0.0058,"timestamp":1771880400000,"preClose":0.0058,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":9878020,"eps":0.36356,"marketStatus":"停牌","change":0,"latestTime":"02-24 08:24:58 EST","open":0.0058,"high":0.0058,"low":0.0058,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.36356,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":0.0058,"volumeRatio":4.567179151938678},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLDI.WS\",,,,,undefined,":{"symbol":"CLDI.WS","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.567179151938678,"shares":9878020,"dividePrice":0,"high":0.0058,"amplitude":0,"preClose":0.0058,"low":0.0058,"week52Low":0.0058,"pbRate":"--","week52High":0.0058,"institutionHeld":0,"latestPrice":0.0058,"eps":0.36356,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.36356,"open":0.0058,"prevYearClose":0.0058,"prevWeekClose":0.0058,"prevMonthClose":0.0058,"prevQuarterClose":0.0058,"fiveDayClose":0.0058,"twentyDayClose":0.0058,"sixtyDayClose":0.0058},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLDI.WS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLDI.WS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLDI.WS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Calidi Biotherapeutics, Inc.成立時是特拉華州的一家臨床階段免疫腫瘤公司，該公司是一家臨床階段的免疫腫瘤學公司，正在開發基於同種異體干細胞的專有平台，以增強和遞送溶瘤病毒以及可能的分子給癌症患者。該公司目前正在開發兩個基於干細胞的專有平台和一個包膜牛痘病毒平台，旨在保護溶瘤病毒，無論是天然的還是工程的，不被患者的免疫防禦所中和，從而允許腫瘤細胞受到更大的感染，並導致溶瘤病毒的抗腫瘤活性比傳統的“裸”溶瘤病毒療法有潛在的改善。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.141864},{"month":2,"riseRate":0.5,"avgChangeRate":0.375366},{"month":3,"riseRate":0,"avgChangeRate":-0.288504},{"month":4,"riseRate":0.666667,"avgChangeRate":0.298619},{"month":5,"riseRate":0,"avgChangeRate":-0.076923},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.085582},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.132847},{"month":8,"riseRate":0.333333,"avgChangeRate":0.085174},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.196177},{"month":10,"riseRate":0,"avgChangeRate":-0.457774},{"month":11,"riseRate":0.5,"avgChangeRate":-0.207855},{"month":12,"riseRate":0.666667,"avgChangeRate":0.701396}],"exchange":"NYSE","name":"CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM)","nameEN":"CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CLDI.WS\",market:\"US\",,,undefined,":null}}